JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants

Trends in Molecular Medicine

Volumn 10, Issue 11, 2004, Pages 532-541

  Borie, Dominic C ^a   O'Shea, John J ^b   Changelian, Paul S ^c  

^a STANFORD UNIVERSITY   (United States)

^b Molec Immunol and Inflammation Br   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ANTIBIOTIC AGENT; ANTILEUKEMIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; JANUS KINASE; JANUS KINASE 3; LEFLUNOMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PNU 156804; PREDNISOLONE; PREDNISONE; PRODIGIOSIN; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG; WHI P 154;

ALLOTRANSPLANTATION; ANEMIA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CELL FUNCTION; CELL POPULATION; DIABETES MELLITUS; DIARRHEA; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE METABOLISM; GROWTH RETARDATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; MEMORY CELL; METABOLIC DISORDER; MOUTH ULCER; NATURAL KILLER CELL; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPENIA; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOCYTOPENIA; WOUND HEALING IMPAIRMENT;

ANIMALS; DRUG DESIGN; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; JANUS KINASE 3; LYMPHOCYTES; ORGAN TRANSPLANTATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS;

JANUS; STAPHYLOCOCCUS PHAGE 3A;

EID: 7244220019     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.09.007     Document Type: Review

References (76)

1. 2003 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993-2002. Department of Health and Human Services, Health Resources and Services Administration Office, Office of Special Programs, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI. (http://www.unos.org/)
2. C. Dambrin Pharmacodynamics of immunosuppressive drugs Curr. Opin. Immunol. 12 2000 557 562
3. R.M. Merion Cyclosporine: five years' experience in cadaveric renal transplantation N. Engl. J. Med. 310 1984 148 154
4. A.O. Ojo Long-term survival in renal transplant recipients with graft function Kidney Int. 57 2000 307 313
5. S. Hariharan Case 4: cardiovascular risk in renal transplantation Transplantation 75 2003 1610 1614
6. P. Libby Chronic rejection Immunity 14 2001 387 397
7. H.A. Valantine Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma" Transplantation 76 2003 891 899
8. W.J. Leonard Dysfunctional cytokine receptor signaling in severe combined immunodeficiency J. Investig. Med. 44 1996 304 311
9. S.M. Russell Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development Science 270 1995 797 800
10. P. Macchi Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 377 1995 65 68
11. J.J. O'Shea Jaks and stats as therapeutic targets Ann. Rheum. Dis. 59 Suppl 1 2000 i115 i118
12. W.J. Leonard X-linked severe combined immunodeficiency: from molecular cause to gene therapy within seven years Mol. Med. Today 6 2000 403 407
13. M. Noguchi Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans Cell 73 1993 147 157
14. W.J. Leonard Jaks and STATs: biological implications Annu. Rev. Immunol. 16 1998 293 322
15. D.S. Aaronson A road map for those who don't know JAK-STAT Science 296 2002 1653 1655
16. S.G. Rane Janus kinases: components of multiple signaling pathways Oncogene 19 2000 5662 5679
17. J.W. Verbsky Nonhematopoietic expression of Janus kinase 3 is required for efficient recruitment of Th2 lymphocytes and eosinophils in OVA-induced airway inflammation J. Immunol. 168 2002 2475 2482
18. J.L. Roberts Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation Blood 103 2004 2009 2018
19. N. Serkova Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides Curr. Opin. Investig. Drugs 4 2003 1287 1296
20. C.M. Horvath The state of the STATs: recent developments in the study of signal transduction to the nucleus Curr. Opin. Cell Biol. 9 1997 233 239
21. J.J. O'Shea Cytokine signaling in 2002: new surprises in the Jak/Stat pathway Cell 109 Suppl. 2002 S121 S131
22. M.K. Kennedy Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice J. Exp. Med. 191 2000 771 780
23. T.A. Waldmann IL-15 in the life and death of lymphocytes: immunotherapeutic implications Trends Mol. Med. 9 2003 517 521
24. T. Ranson IL-15 is an essential mediator of peripheral NK-cell homeostasis Blood 101 2003 4887 4893
25. A.M. Baird A profound deficiency in thymic progenitor cells in mice lacking Jak3 J. Immunol. 165 2000 3680 3688
26. + cells J. Exp. Med. 195 2002 1523 1532
27. D.C. Thomis Peripheral expression of Jak3 is required to maintain T lymphocyte function J. Exp. Med. 185 1997 197 206
28. K. Ozaki A critical role for IL-21 in regulating immunoglobulin production Science 298 2002 1630 1634
29. M. Strengell IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells J. Immunol. 170 2003 5464 5469
30. J. Parrish-Novak Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function Nature 408 2000 57 63
31. J. Brady IL-21 induces the functional maturation of murine NK cells J. Immunol. 172 2004 2048 2058
32. A. Valujskikh In remembrance of things past: memory T cells and transplant rejection Immunol. Rev. 196 2003 65 74
33. + effector and memory T cell generation Nat. Immunol. 4 2003 835 842
34. A.W. Goldrath Cytokine requirements for acute and basal homeostatic proliferation of naive and memory CD8(+) T cells J. Exp. Med. 195 2002 1515 1522
35. Z.H. Wu Homeostatic proliferation is a barrier to transplantation tolerance Nat. Med. 10 2004 87 92
36. J.M. Curtsinger Signal 3 determines tolerance versus full activation of naive CD8 T cells: Dissociating proliferation and development of effector function J. Exp. Med. 197 2003 1141 1151
37. + regulatory T cell homeostasis and the maintenance of self-tolerance J. Immunol. 171 2003 3435 3441
38. + suppressor T cells J. Exp. Med. 193 2001 F41 F46
39. S.R. Hubbard Structural analysis of receptor tyrosine kinases Prog. Biophys. Mol. Biol. 71 1999 343 358
40. N. Meydan Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor Nature 379 1996 645 648
41. R.A. Kirken Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells J. Leukoc. Biol. 65 1999 891 899
42. F. Behbod Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts J. Immunol. 166 2001 3724 3732
43. A. Mortellaro New immunosuppressive drug PNU156804 blocks IL-2-dependent proliferation and NF-kappa B and AP-1 activation J. Immunol. 162 1999 7102 7109
44. R.T. Elder The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms J. Immunol. 159 1997 22 27
45. K. Siemasko Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production J. Immunol. 160 1998 1581 1588
46. E.A. Sudbeck Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents Clin. Cancer Res. 5 1999 1569 1582
47. F.M. Uckun In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4′hydroxyphenyl)-amino-6,7- dimethoxyquinazoline Clin. Cancer Res. 5 1999 2954 2962
48. M. Cetkovic-Cvrlje Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice Blood 98 2001 1607 1613
49. M. Cetkovic-Cvrlje Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice Clin. Immunol. 106 2003 213 225
50. T. Habib The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3 Biochemistry 41 2002 8725 8731
51. M.D. Saemann Suppression of early T-cell-receptor-triggered cellular activation by the Janus kinase 3 inhibitor WHI-P-154 Transplantation 75 2003 1864 1872
52. R. Malaviya Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria Immunity 15 2001 313 321
53. R. Malaviya Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis J. Biol. Chem. 274 1999 27028 27038
54. R. Malaviya Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions Biochem. Biophys. Res. Commun. 257 1999 807 813
55. M.D. Saemann Prevention of CD40-triggered dendritic cell maturation and induction of T-cell hyporeactivity by targeting of Janus kinase 3 Am. J. Transplant. 3 2003 1341 1349
56. H.H. Jabara Role of JAK3 in CD40-mediated signaling Blood 92 1998 2435 2440
57. H.E. Tibbles Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation J. Biol. Chem. 276 2001 17815 17822
58. P.S. Changelian Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 302 2003 875 878
59. P.M. Nurse Nobel Lecture. Cyclin dependent kinases and cell cycle control Biosci. Rep. 22 2002 487 499
60. D. Borie Targeted inhibition of JAK3 with CP - 690,550 significantly prolongs allograft survival in a nonhuman primate model of renal transplantation Am. J. Transplant. 3 Suppl. 5 2003 152
61. E. Kudlacz The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models Am. J. Transplant. 4 2004 51 57
62. J.W. Verbsky Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells J. Biol. Chem. 271 1996 13976 13980
63. Borie, D.C. et al. Immuno-suppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation (in press)
64. H. Podder Selective Janus kinase 3 (JAK3) antagonist acts synergistically with cyclosporine (CsA) but lacks side effects associated with CsA/Sirolimus combination Am. J. Transplant. 4 Suppl. 8 2004 286
65. M.L. Vampa Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch Transplantation 76 2003 1220 1228
66. H.J. Schuurman Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation Transplantation 69 2000 737 742
67. G.M. Williams Hyperacute renal-homograft rejection in man N. Engl. J. Med. 279 1968 611 618
68. M. Crespo Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics Transplantation 71 2001 652 658
69. S. Mauiyyedi Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries J. Am. Soc. Nephrol. 12 2001 574 582
70. C.L. Hsieh NK cells and transplantation Transpl. Immunol. 9 2002 111 114
71. Y. Ogura Apoptosis and allograft rejection in the absence of CD8+ T cells Transplantation 71 2001 1827 1834
72. C.M. Wood Jak3 expression and genomic sequence in pediatric acute lymphoblastic leukemia Leuk. Lymphoma 43 2002 2355 2362
73. F.M. Uckun Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model Blood 99 2002 4192 4199
74. X.C. Li Blocking the common γ-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival J. Immunol. 164 2000 1193 1199
75. D.F. Zeng Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus J. Clin. Invest. 112 2003 1211 1222
76. J.J. O'Shea Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? Immunity 7 1997 1 11